BioCentury | Dec 22, 2018
Financial News

Gossamer Bio seeks $264.5 million IPO one year after launch

...placebo of improvement in forced expiratory volume over one second (FEV1) in asthma patients. From Pulmokine Inc....
...sublicenses to GB002 for $5.5 million up front and up to $298 million in milestones. Pulmokine...
BioCentury | Mar 9, 2015
Financial News

Pulmokine completes venture financing

Pulmokine Inc. , Rensselaer, N.Y. Business: Cardiovascular Date completed: 2015-03-03 Type: Venture financing Raised: $1 million Investor: Broadview Ventures Inc. WIR Staff...
BioCentury | Apr 7, 2014
Company News

Pulmokine, NIH cardiovascular news

...Under the three-year contract, Pulmokine will develop its undisclosed lead candidate into Phase I testing. Pulmokine...
...Cytopia in 2010 and Gilead Sciences Inc. (NASDAQ:GILD, Foster City, Calif.) acquired YM last year. Pulmokine Inc....
Items per page:
1 - 3 of 3
BioCentury | Dec 22, 2018
Financial News

Gossamer Bio seeks $264.5 million IPO one year after launch

...placebo of improvement in forced expiratory volume over one second (FEV1) in asthma patients. From Pulmokine Inc....
...sublicenses to GB002 for $5.5 million up front and up to $298 million in milestones. Pulmokine...
BioCentury | Mar 9, 2015
Financial News

Pulmokine completes venture financing

Pulmokine Inc. , Rensselaer, N.Y. Business: Cardiovascular Date completed: 2015-03-03 Type: Venture financing Raised: $1 million Investor: Broadview Ventures Inc. WIR Staff...
BioCentury | Apr 7, 2014
Company News

Pulmokine, NIH cardiovascular news

...Under the three-year contract, Pulmokine will develop its undisclosed lead candidate into Phase I testing. Pulmokine...
...Cytopia in 2010 and Gilead Sciences Inc. (NASDAQ:GILD, Foster City, Calif.) acquired YM last year. Pulmokine Inc....
Items per page:
1 - 3 of 3